Downregulation of CD19 Expression Associates With Mantle Cell Lymphoma Relapse Following CAR‐T Cell Therapy

European Journal of Immunology 2026

View at publisher
Authors: Benedetta Peruzzi, Alessio Mazzoni, Ilaria Cutini, Francesca Matani, Roberto Caporale, Sara Bencini, Sara Pratesi, Laura Maggi, Manuela Capone, Anna Vanni, Giulia Lamacchia, Lucia Bartoli
+9 more Francesco Liotta, Lorenzo Cosmi, Benedetta Puccini, Luca Nassi, Benedetta Sordi, Chiara Camerini, A M Vannucchi, Chiara Nozzoli, Francesco Annunziato
DOI: 10.1002/eji.70123
Cited by: 1
References: 4

Abstract

We report the case of a stage 4 mantle cell lymphoma patient, resistant to conventional first- and second-line therapies, treated with CAR-T cells. The therapy was initially efficacious, with an appreciable CAR-T cells expansion in vivo. However, downregulation of CD19 expression on malignant B cells led to sudden therapy failure.

Fields of Study & Subjects

CAR-T cell therapy research Cutaneous lymphoproliferative disorders research Lymphoma Diagnosis and Treatment

Publication details

Journal / source
European Journal of Immunology
Publisher
Wiley
Volume
56
Issue
1
Pages
e70123–e70123
Publication date
1 January 2026
Language
EN